Maraviroc: The first chemokine coreceptor 5 inhibitor

Brianna L. Norton, Charles B. Hicks

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

HIV viral entry occurs via viral interaction with host cell CD4 receptors and a second coreceptor, most commonly chemokine coreceptor (CCR)5. As a result, CCR5 antagonists have been developed to block HIV entry into CD4+ cells, thereby inhibiting viral replication. The first CCR5 inhibitor approved for use in the treatment of HIV was maraviroc. Maraviroc has been shown to be successful in reducing HIV replication in both antiretroviral treatment-experienced and treatment-naive populations. Since maraviroc is only efficacious against CCR5-tropic HIV virus, it is imperative to perform viral tropism testing prior to initiation of maraviroc. The currently available enhanced sensitivity Trofile™ assay (Monogram Biosciences, CA, USA) is the reference standard of tropism tests. Although it is highly sensitive, it remains a barrier to maraviroc use because it is expensive and has a long turnaround time. The development of simpler tropism assays may allow for more widespread use of maraviroc in the future. At present, maraviroc remains a highly useful drug in the management of HIV-infected persons infected with CCR5-tropic viruses.

Original languageEnglish (US)
Pages (from-to)283-294
Number of pages12
JournalFuture Virology
Volume6
Issue number3
DOIs
StatePublished - Mar 2011
Externally publishedYes

Fingerprint

Chemokines
HIV
Tropism
Viral Tropism
Viruses
CD4 Antigens
maraviroc
Pharmaceutical Preparations
Population

Keywords

  • CCR5 receptor
  • maraviroc
  • tropism

ASJC Scopus subject areas

  • Virology

Cite this

Maraviroc : The first chemokine coreceptor 5 inhibitor. / Norton, Brianna L.; Hicks, Charles B.

In: Future Virology, Vol. 6, No. 3, 03.2011, p. 283-294.

Research output: Contribution to journalArticle

Norton, Brianna L. ; Hicks, Charles B. / Maraviroc : The first chemokine coreceptor 5 inhibitor. In: Future Virology. 2011 ; Vol. 6, No. 3. pp. 283-294.
@article{8b14f272c9f44449a400e1343c239f03,
title = "Maraviroc: The first chemokine coreceptor 5 inhibitor",
abstract = "HIV viral entry occurs via viral interaction with host cell CD4 receptors and a second coreceptor, most commonly chemokine coreceptor (CCR)5. As a result, CCR5 antagonists have been developed to block HIV entry into CD4+ cells, thereby inhibiting viral replication. The first CCR5 inhibitor approved for use in the treatment of HIV was maraviroc. Maraviroc has been shown to be successful in reducing HIV replication in both antiretroviral treatment-experienced and treatment-naive populations. Since maraviroc is only efficacious against CCR5-tropic HIV virus, it is imperative to perform viral tropism testing prior to initiation of maraviroc. The currently available enhanced sensitivity Trofile™ assay (Monogram Biosciences, CA, USA) is the reference standard of tropism tests. Although it is highly sensitive, it remains a barrier to maraviroc use because it is expensive and has a long turnaround time. The development of simpler tropism assays may allow for more widespread use of maraviroc in the future. At present, maraviroc remains a highly useful drug in the management of HIV-infected persons infected with CCR5-tropic viruses.",
keywords = "CCR5 receptor, maraviroc, tropism",
author = "Norton, {Brianna L.} and Hicks, {Charles B.}",
year = "2011",
month = "3",
doi = "10.2217/fvl.11.2",
language = "English (US)",
volume = "6",
pages = "283--294",
journal = "Future Virology",
issn = "1746-0794",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Maraviroc

T2 - The first chemokine coreceptor 5 inhibitor

AU - Norton, Brianna L.

AU - Hicks, Charles B.

PY - 2011/3

Y1 - 2011/3

N2 - HIV viral entry occurs via viral interaction with host cell CD4 receptors and a second coreceptor, most commonly chemokine coreceptor (CCR)5. As a result, CCR5 antagonists have been developed to block HIV entry into CD4+ cells, thereby inhibiting viral replication. The first CCR5 inhibitor approved for use in the treatment of HIV was maraviroc. Maraviroc has been shown to be successful in reducing HIV replication in both antiretroviral treatment-experienced and treatment-naive populations. Since maraviroc is only efficacious against CCR5-tropic HIV virus, it is imperative to perform viral tropism testing prior to initiation of maraviroc. The currently available enhanced sensitivity Trofile™ assay (Monogram Biosciences, CA, USA) is the reference standard of tropism tests. Although it is highly sensitive, it remains a barrier to maraviroc use because it is expensive and has a long turnaround time. The development of simpler tropism assays may allow for more widespread use of maraviroc in the future. At present, maraviroc remains a highly useful drug in the management of HIV-infected persons infected with CCR5-tropic viruses.

AB - HIV viral entry occurs via viral interaction with host cell CD4 receptors and a second coreceptor, most commonly chemokine coreceptor (CCR)5. As a result, CCR5 antagonists have been developed to block HIV entry into CD4+ cells, thereby inhibiting viral replication. The first CCR5 inhibitor approved for use in the treatment of HIV was maraviroc. Maraviroc has been shown to be successful in reducing HIV replication in both antiretroviral treatment-experienced and treatment-naive populations. Since maraviroc is only efficacious against CCR5-tropic HIV virus, it is imperative to perform viral tropism testing prior to initiation of maraviroc. The currently available enhanced sensitivity Trofile™ assay (Monogram Biosciences, CA, USA) is the reference standard of tropism tests. Although it is highly sensitive, it remains a barrier to maraviroc use because it is expensive and has a long turnaround time. The development of simpler tropism assays may allow for more widespread use of maraviroc in the future. At present, maraviroc remains a highly useful drug in the management of HIV-infected persons infected with CCR5-tropic viruses.

KW - CCR5 receptor

KW - maraviroc

KW - tropism

UR - http://www.scopus.com/inward/record.url?scp=79953309132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953309132&partnerID=8YFLogxK

U2 - 10.2217/fvl.11.2

DO - 10.2217/fvl.11.2

M3 - Article

AN - SCOPUS:79953309132

VL - 6

SP - 283

EP - 294

JO - Future Virology

JF - Future Virology

SN - 1746-0794

IS - 3

ER -